(Q86172984)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25468161%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Starting the battle to control non-alcoholic steatohepatitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25468161%20AND%20SRC:MED&resulttype=core&format=json

non-alcoholic steatohepatitis

24 February 2020

main subject

1 reference

Vlad Ratziu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25468161%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

language of work or name

English

0 references

publication date

7 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25468161%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25468161%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

385

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25468161%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

9972

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25468161%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

922-924

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25468161%20AND%20SRC:MED&resulttype=core&format=json

Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962010-9

7 January 2021

Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962010-9

7 January 2021

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962010-9

7 January 2021

Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962010-9

7 January 2021

Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962010-9

7 January 2021

Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962010-9

7 January 2021

Long-term follow-up of patients with NAFLD and elevated liver enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962010-9

7 January 2021

Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962010-9

7 January 2021

Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962010-9

7 January 2021

Antiatherosclerotic effect of farnesoid X receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962010-9

7 January 2021

Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962010-9

7 January 2021

10.1016/S0140-6736(14)62010-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25468161%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference